DALLAS, June 21, 2011 (GLOBE NEWSWIRE) -- John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB:VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.
Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.
Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicor's PD2i Analyzer™ to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer™ as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer™ to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.
Sixty published manuscripts of studies involving the use of Vicor's PD2i® nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.
To view the video interview, please visit:
Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. Total compensation is seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031.
CONTACT: Shareholder Vision John Pentony, Publisher email@example.com Tel: (469) 250-3030